Provention Bio Inc (NASDAQ:PRVB) Unveils Phase 2b PROACTIVE Study Of PRV-015

Provention Bio Inc (NASDAQ:PRVB) focuses on ways to help patients struggling with a condition known as the ‘Non-Responsive Celiac Disease’ (NRCD). This group of patients doesn’t respond well to a gluten-free diet, and the company supports them in focusing on its Phase 2b PROACTIVE (PROvention Amgen Celiac ProtecTIVE) study of PRV-015.

PRV-015 stands out

The striking of a business alliance between this company and Amgen has played a huge role in making the PRV-015 a success. Sources point out to the Celiac disease as being one of those serious autoimmune diseases affecting many people globally, yet treatment hasn’t been established yet.

Some of the patients have tried out the gluten-free diets over the past years, but that hasn’t helped much. Most of them admit that they couldn’t effectively manage the disease, which is why the company thought about developing a remedy for them.

The truth is that the consumption of gluten in foods is rather wide-spread. It is also noteworthy that most of the consumer products and medications also contaminated. What makes the situation even worse is the point that there are even products perceived as being glutenfree, yet they are contaminated.

Dealing with the contaminating gluten

Research shows things can get devastating when dealing with non-responsive celiac disease. Some may want to activate the immune system by gluten, which will probably pose some long-term effects. A good example would be the development of intestinal lymphoma, which could cause great patient discomfort.

Based on data provided in the past, PRV-015 has come out clearly as an interesting therapeutic candidate that could work in helping intercept the serious and severe effects of the contaminating gluten.

In case all goes according to plan, PRV-015 may just turn out to be the first therapeutic for celiac disease to get approved. The investigational candidate stands out as the only one that has simultaneously tone down the intestinal inflammation markers and the gluten-induced symptoms. That is when brought into close comparison with a placebo. The company hopes to soon engage in the expansion of its clinical experience with the product.